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Background: Nipah virus (NiV) is a zoonotic virus belonging to the henipavirus genus in the family Paramyxoviridae.
Since NiV was first identified in 1999, outbreaks have continued to occur in humans in Bangladesh and India on an
almost annual basis with case fatality rates reported between 40% and 100%.
Methods: Ferrets were vaccinated with 4, 20 or 100 μg HeVsG formulated with the human use approved adjuvant,
CpG, in a prime-boost regime. One half of the ferrets were exposed to NiV at 20 days post boost vaccination and
the other at 434 days post vaccination. The presence of virus or viral genome was assessed in ferret fluids and
tissues using real-time PCR, virus isolation, histopathology, and immunohistochemistry; serology was also carried
out. Non-immunised ferrets were also exposed to virus to confirm the pathogenicity of the inoculum.
Results: Ferrets exposed to Nipah virus 20 days post vaccination remained clinically healthy. Virus or viral genome
was not detected in any tissues or fluids of the vaccinated ferrets; lesions and antigen were not identified on
immunohistological examination of tissues; and there was no increase in antibody titre during the observation
period, consistent with failure of virus replication. Of the ferrets challenged 434 days post vaccination, all five
remained well throughout the study period; viral genome – but not virus - was recovered from nasal secretions of
one ferret given 20 μg HeVsG and bronchial lymph nodes of the other. There was no increase in antibody titre
during the observation period, consistent with lack of stimulation of a humoral memory response.
Conclusions: We have previously shown that ferrets vaccinated with 4, 20 or 100 μg HeVsG formulated with CpG
adjuvant, which is currently in several human clinical trials, were protected from HeV disease. Here we show, under
similar conditions of use, that the vaccine also provides protection against NiV-induced disease. Such protection
persists for at least 12 months post-vaccination, with data supporting only localised and self-limiting virus
replication in 2 of 5 animals. These results augur well for acceptability of the vaccine to industry.
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Nipah virus (NiV) is a zoonotic virus belonging to the
henipavirus genus in the family Paramyxoviridae.
Hendra virus (HeV) is the only other recognised mem-
ber of the henipavirus genus [1], although there is in-
creasing evidence of a range of henipa-like and other
paramyxoviruses [2-6], particularly in bats which are
the reservoir host for both NiV and HeV. HeV and NiV
are classified as BioSafety Level 4 (BSL-4) agents, a
designation that reflects their ability to cause signifi-
cant morbidity and mortality in humans as well as the
absence of vaccines and post-exposure treatments.
Since NiV was first identified [7] outbreaks have oc-
curred in humans on an almost annual basis with case
fatality rates generally reported between 40% and 100%
[8]. Human-to-human transmission, although not yet
observed for HeV [9,10], has been recorded in NiV
outbreaks in Bangladesh. Here the local custom of
family nursing infected members has resulted in ex-
tended exposure to infectious bodily secretions, par-
ticularly respiratory fluids [11]. Documentation of
human-to-human transmission in this highly virulent
group of viruses confirms the possibility of sustained
endemic human-to-human transmission and the at-
tendant consequences.
Vaccination is an important component of outbreak
preparedness and considerable data has now been ac-
cumulated on a subunit vaccine incorporating the G
glycoprotein of HeV (HeVsG). The HeVsG vaccine has
so far proved effective in preventing disease following
exposure to both HeV and NiV. This is as predicted
because the G glycoproteins of NiV and HeV share
83% amino acid identity [12] and also host cell recep-
tors - ephrin B2 and ephrin B3 [13-15]. Cats vacci-
nated with HeVsG produced high levels of neutralising
antibody to both HeV and NiV [16]; neutralising anti-
body to surface glycoprotein has been shown to be
particularly effective in protecting against infection
with viruses like the henipaviruses that have a viraemic
phase [17-19]. Most vaccinated animals not only
remained clinically well following exposure to virus
but had no evidence of infection, including no boost in
vaccinal antibody titres. Vaccination with HeVsG has
also been shown to prevent NiV infection in cats and
nonhuman primates, and HeV infection in ferrets
[16,20-22] and horses. In this last case, HeVsG antigen
forms the basis of a commercially available vaccine for
HeV - the first vaccine licensed and deployed for use
against a BSL-4 agent (Middleton et al., manuscript in
preparation). Here we show that ferrets vaccinated
with HeVsG were equally protected against NiV dis-
ease at 20 days post vaccination as against HeV [22].
Furthermore, protection from disease persisted for
over 12 months.Results
Nipah virus challenge of immunized ferrets
The aim of this study was to determine whether a
HeVsG based vaccine protected ferrets against disease
caused by NiV and the duration of any vaccine-induced
protection. Eight ferrets were exposed to an otherwise
lethal dose of NiV at either 20 days post vaccination
(study 1) or 14 months post vaccination (study 2).
Study 1: Two control ferrets 1–0 and 2–0 were given
only adjuvant; 1–0 was febrile on day 5 pi and was eutha-
nized on day 6 pi, while 2–0 was febrile on days 7 and 8 pi
and was euthanized on day 10 pi. Two vaccinated ferrets,
4–4 and 7–100 were euthanized prior to exposure to virus
for reasons unassociated with the scientific study. The
remaining vaccinated ferrets, 3–4, 5–20, 6–20 and 8–100
remained clinically healthy and were electively euthanized
on day 41 of the study.
Study 2: Two control ferrets, 9–0 and 10–0 became fe-
brile and exhibited reduced playfulness by day 8 pi; both
were euthanized. Ferret 15–100 was euthanized prior to
exposure to virus for reasons unassociated with the sci-
entific study. The remaining vaccinated ferrets, 11–4,
12–4, 13–20, 14–20 and 16–100 remained clinically
healthy and were electively euthanized on day 455
(21 days pi) of the study.
Gross pathology, histopathology and
immunohistochemistry
Study 1. Control ferrets 1–0 and 2–0 both had histo-
logical lesions including widespread deposition of NiV
antigen consistent with acute NiV infection as previously
described [23]. No significant histological lesions were
detected in the remaining 4 ferrets, 3–4, 5–20, 6–20 and
8–100 and NiV antigen was not detected in any of their
tissues.
Study 2. Control ferrets 9–0 and 10–0 both had histo-
logical lesions including widespread deposition of NiV
antigen consistent with acute NiV infection as previously
described [23]. No significant histological lesions were
detected in the tissues of vaccinated ferrets, 11–4, 12–4,
13–20, 14–20, and 16–100 and NiV antigen was not
detected in any of their tissues.
Viral RNA detection and virus isolation
Viral RNA detection results for study 1 are shown in
Table 1. Viral RNA was found in all fluids, swabs and
tissues of control ferrets 1–0 and 2–0 and virus was re-
isolated from tissues collected from them post mortem.
Ct results for positive samples and tissues are shown in
Table 2. Where virus was isolated from viral RNA posi-
tive samples the titre was generally not greater than 105
TCID50/ml. These data confirm that virus exposure was
sufficient to induce serious infection in the naïve animal.
In contrast viral RNA was not detected in any swabs,
Table 1 Study 1: Genome detection in ferrets challenged at day 20 post vaccination
Ferret# - dose
HeVsG












1-0 <2 6 PM PM PM PM PM 13/13 8/13
2-0 <2 10 6, 8, PM 8, PM 8, PM 8, PM PM 13/13 6/13
3-4 64, 64 21 - - - - - 0/13 ND
4-4 NC na NC NC NC NC NC NC ND
5-20 256, 256 21 - - - - - 0/13 ND
6-20 256, 512 21 - - - - - 0/13 ND
7-100 NC na NC NC NC NC NC NC ND
8-100 256, 512 21 - - - - - 0/13 ND
Ab antibody, Eut dpc day post challenge that ferrets were euthanized PM post mortem, NC no challenge, ND not done; -, no viral RNA detected, na not applicable.
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either during the immediate post-exposure period or at
post mortem examination; this included ferret 3–4
which had received the lowest dose (4 μg) of HeVsG.
Viral RNA detection results for study 2 are shown in
Table 3; the pattern of genome detection and virus re-
isolation from the control ferrets 9–0 and 10–0 confirmed
an otherwise lethal exposure to NiV. Viral genome was
not detected in any swabs, fluids or tissues from 3 of the 5
vaccinated ferrets. In one animal (ferret 14–20), viral gen-
ome was detected in nasal washes at day 6 and day 8 pi
and, in another (ferret 13–20), from the bronchial lymph
nodes at post mortem. In neither case was virus re-
isolated from these samples. Ct results for positive samples
and tissues are shown in Table 2. Where virus was isolated
from viral RNA positive samples the titre was generally
not greater than 105 TCID50/mlTable 2 Ct values in genome positive samples in studies 1 an
Sample Sample day
1–0 2–0
Oral swab D6 - 31.4
D8 - 34.8
PM 33.6 30.5
Rectal swab D6 - -
D8 - 37.5
PM 33.3 31.2
Blood D6 - -
D8 - 32.9
PM 30.2 30.1
Nasal wash D6 - -
D8 - 36.4
PM 28.0 29.6
Urine PM 31.0 29.1
Tissues PM 118-34.7 18.0-30.9
1-0, 2–0 = control ferrets, study 1; 9–0, 10–0 = control ferrets, study 2; 13–20, 13–20
detected. 1Range of Ct values in tissues;
2bronchial lymph nodes.Post-challenge serology
In both studies sera were collected at the time of expos-
ure to virus; day 6, 8 and 10 pi, and at euthanasia. There
was no clear cut evidence of an anamnestic antibody re-
sponse in either group.
Conclusions
As the human population expands into previously un-
touched environments there are increasing reports of
viruses that have co-existed for long periods of time in
their reservoir hosts ‘spilling over’ to emerge as novel
human infections. The recent example of such an agent,
human immunodeficiency virus (HIV), demonstrates the
devastating economic and social impact that these
events may have on human populations. Although the
virus was not identified until 1981, HIV is thought to
have made the initial jump from chimpanzees intod 2
Genome detected by PCR (Ct)
9–0 10–0 13–20 14–20
- 32.6 - -
- - - -
38.0 31.9 - -
- 35.8 - -
- - - -
- 35.4 - -
- 36.6 - -
38.3 - - -
- 26.5 - -
- 29.4 - 34.1
- - - 32.3
31.9 31.9 - -
34.7 31.9 - -
18.6-36.6 16.4-37.8 233.8 -
= ferrets receiving 20 μg HeVsG in study 2. PM post mortem; -, no viral RNA
Table 3 Study 2: Genome detection in ferrets challenged at 434 days post vaccination
Ferret # - dose
HeVsG










9-0 <4, <4 8 PM - PM PM PM 13/13 10/13
10-0 <4, <4 8 6, PM 6,PM 6, PM 6, PM PM 13/13 10/13
11-4 32, 128 20 - - - - - - ND
12-4 32, 64 20 - - - - - - ND
13-20 16, 16 20 - - - - - 1/13 0/13
14-20 64, 128 20 - - - 6,8 - - -
15-100 NC na NC NC NC NC NC NC NC
16-100 64, 64 20 - - - - - - ND
Ab antibody, Eut dpc day post challenge that ferrets were euthanized, PM post mortem, ND not done, NC no challenge; -, no viral RNA detected, na not applicable.
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34 million people were living with acquired immunodefi-
ciency syndrome (AIDS) and in the same year 2.4-2.9
million people were newly infected with HIV. HeV and
NiV were also discovered relatively recently – HeV was
isolated and identified in 1994 when it caused the death
of 20 horses and 1 human [24] and NiV in 1998–9 after
an outbreak in pigs and humans in Peninsular Malaysia
and Singapore [7]. They were identified as paramyxovi-
ruses but were sufficiently distinct to be assigned to a
new genus, Henipavirus, within the Paramyxoviridae
[25,26]. Their large genome was atypical as was their
pathogenicity for a range of species, with reported mor-
tality rates in humans of up to 100% for NiV and 57%
for HeV. All human cases of HeV infection to date have
resulted from close contact with secretions of infected
horses either late in incubation period, during terminal
illness, or at post mortem examination. There is no
known instance of transmission directly to humans from
the reservoir host, the bat, or of human-to-human trans-
mission of HeV. In contrast, NiV in Bangladesh can be
transmitted directly from bats to people and this has
been linked epidemiologically to the consumption of
contaminated palm sap; human-to-human transmission
also occurs here and is thought to be facilitated by fam-
ilies nursing sick relatives with attendant copious expos-
ure to infected bodily fluids [27]. Repeated spillover
events into human (and other animal populations) have
been documented for both HeV and NiV [8] suggesting
persistence of the environmental circumstances that
facilitated the initial emergence event. Spillover is thus
likely to be ongoing, and it is conceivable that a future
incident with increasing host adaptation might result in
establishment of HeV or NiV in human populations,
with an impact exacerbated by high mortality rates and
no pre-existing immunity.
The sporadic occurrence of viral spillover events creates
major challenges for emergency disease preparednessactivities. However, in the 15–20 years since HeV and NiV
were first identified substantial progress has been made in
the development of vaccines and therapeutics for the pre-
vention and treatment of infection with these viruses. The
HeVsG vaccine, which prevents HeV disease in horses, is
the first to be registered for use against a BSL-4 agent,
and a therapeutic monoclonal antibody is currently being
assessed for human use [23,28]. While the focus in
Australia is on management of the infection risks posed
by HeV infection, studies have shown that the HeVsG vac-
cine provides equally powerful cross-protection against
NiV infection in cats and nonhuman primates.
Our current studies indicate that at the time of onset
of protection the HeVsG vaccine can reliably protect fer-
rets from acute NiV disease and also prevent infection –
providing so-called sterilizing immunity - consistent
with earlier studies using HeV [22]. Here we have also
shown, in the first duration of protection study in an
animal model, protection from disease persists at least
14 months after vaccination in ferrets. Recovery of viral
genome (but not live virus) from the nasal washes of
one animal and from the bronchial lymph nodes of an-
other, in the absence of a rise in antibody titre, are con-
sistent with self-limiting local virus replication at a level
insufficient to generate an anamnestic immune response
or to sustain a transmission event.
The animal numbers reported here are necessarily
small due partly to the limitations of the BSL4 facility
but also because 3 ferrets were euthanized before chal-
lenge leaving 3 groups in the 2 studies with a group size
of 1. While no conclusion can be drawn from a group
size of 1 there were 3 remaining groups where n = 2, the
20 μg group in both studies and the 4 μg group in study
2. Data from these groups indicated that the vaccine in-
duced protection sufficient to suppress the course of a
human pandemic persists for at least 12 months. The
data from the reduced groups also support this
conclusion.
Pallister et al. Virology Journal 2013, 10:237 Page 5 of 7
http://www.virologyj.com/content/10/1/237Importantly, in the event of a spillover leading to
sustained human-to-human transmission of HeV or NiV,
proof of concept studies already exist for the sG subunit
vaccine in two animal models of which one is a non-
human primate. This is relevant to the US FDA animal
rule that states where a medical countermeasure cannot
be evaluated in humans, in vivo evaluation of a vaccine
or therapeutic may be translated from the outcomes of
work in two animal models. Finally, the experimental
vaccine given to ferrets uses a formulation that is in clin-
ical trials in humans.
Recrudescence in the form of encephalitis has been doc-
umented for both HeV and NiV and is thought to be due
to persistence of the virus in some form within the central
nervous system. A farmer from Mackay, Australia devel-
oped encephalitis 13 months after apparent recovery from
acute meningencephalitis caused by HeV and died with
evidence of HeV in the brain as detected by PCR, electron
microscopy and immunohistochemistry [29]. In the initial
NiV outbreak in Malaysia 7.5% of survivors went on to de-
velop relapsing encephalitis and 3.4% suffered late-onset
encephalitis months to years after recovery from the initial
infection [30,31]. Recent studies have shown that HeV can
infect the mouse brain via an anterograde route of infec-
tion, probably along the olfactory nerve [32] as also
suggested for NiV in pigs [33]. This suggests that an
effective henipavirus vaccine will need to suppress the
initial phase of replication in the upper respiratory
tract (summarized in [8]) to a level that prevents infec-
tion of olfactory sensory neurons as well as preventing
the onset of viremia.
The HeVsG subunit vaccine has proved highly effective
in suppression of virus replication and disease preven-
tion, with duration of protection that is sufficient to
make the formulation attractive to industry. A vaccine
incorporating the HeVsG antigen has now been released
for use in horses and its application and observed effect-
iveness, along with ongoing work in animal models in-
cluding nonhuman primates, will enable a more rapid
response to any future henipavirus spillover events that
threaten to cause large scale outbreaks in humans.
Methods
Animals, accommodation, handling and biosafety
Eight male ferrets aged 12 – 18 months were used in
each of 2 experiments. Those exposed to NiV at 20 days
post vaccination (study 1) were housed in pairs in cages
in a single room at PC-3 or 4 for the duration of the
study. Those exposed to NiV at 413 days post vaccin-
ation (study 2) were housed in pairs in cages at PC2
until the time of virus exposure, when they were moved
to a single room at BSL-4. Animal husbandry was car-
ried out as described in [22], and animal husbandry
methods and experimental design were endorsed by theAustralian Animal Health Laboratory’s Animal Ethics
Committee.
Animal infection
All ferrets were exposed to 5000 TCID50 of a low pas-
sage isolate of NiV-Bangladesh/human/2004/Rajbari, R1
[34,35]. This represents 10 times the minimum infec-
tious dose determined for this virus in ferrets. General
clinical observations were documented daily before and
after infection (pi). Animals were weighed while under
sedation at the time of vaccinations, virus exposure, and
at days 6, 8, 10 and 21 pi. Rectal temperature was also
recorded at sedation to augment data derived remotely
from the implanted temperature transponders. Ferrets
were euthanized when reaching a previously determined
endpoint or at 21 days pi. The humane endpoint was de-
fined as rapidly progressive clinical illness of up to 2
days duration including fever and depression, possibly
accompanied by increased respiratory rate or posterior
paresis or ataxia. In susceptible animals, this typically oc-
curs within the first 10 days after viral challenge. In pre-
liminary studies, these signs were found to correlate
with the requirement to euthanize ferrets on subsequent
days on humane grounds; thus, they have been utilized
as surrogates for lethality.
Vaccine immunogen preparation
A human codon optimized HeV soluble glycoprotein G
(sG) construct was used to produce recombinant HeVsG
as described [22]. CpG oligodeoxynucleotide (ODN)
2007 (TCGTCGTTGTCGTTTTGTCGTT) containing a
fully phosphorothioate backbone was purchased from
Invivogen (San Diego, CA, USA) and AlhydrogelTM was
purchased from Accurate Chemical & Scientific Corpor-
ation (Westbury, NY, USA). Vaccine doses containing
fixed amount of CpG ODN 2007 and varying amounts
of HeVsG and aluminum ion (at a weight ratio of 1:25)
were formulated as follows: 4 μg sGHeV, 100 μg alumin-
ium ion and 150 μg of CpG ODN 2007; 20 μg dose: 20
μg sGHeV, 500 μg aluminium ion and 150 μg of CpG
ODN2007; and 100 μg dose: 100 μg HeVsG, 2.5 mg alu-
minium ion and 150 μg of CpG ODN 2007. For all
doses, AlhydrogelTM and sGHeV were mixed first before
CpG ODN 2007 was added. Each vaccine dose was ad-
justed to 1 ml with PBS and mixtures were incubated on
a rotating wheel at room temperature for at least 2–3 h
prior to injection.
Immunisation
For both studies, ferrets were divided randomly into 4
groups of 2, with each group receiving vaccine or adju-
vant alone as follows: study 1 – 1–0 and 2–0 received
adjuvant only, 3–4 and 4–4 were vaccinated with 4 μg
HeVsG, 5–20 and 6–20 with 20 μg HeVsG and 7–100
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rets numbered 9–0 and 10–0, 11–4 and 12–4, 13–20
and 14–20, 15–100 and 16–100 received 0, 4, 20 and
100 μg HeVsG respectively. The vaccine was adminis-
tered subcutaneously with a priming dose at day 0 and a
booster dose 20 days later.
Sample collection
Nasal washes, oral and rectal swabs and blood samples
both in EDTA and for serum preparation, were taken at
the time of vaccination and virus exposure, then at days
6, 8, 10 and 21 pi as described in [22]. Urine was col-
lected only at post mortem examination when tissues
were also collected for virus isolation, viral genome
detection, histology, and immunohistology as described
in [22]. These tissues included adrenal gland, bladder,
brain, olfactory pole, heart, kidney, liver, apical lung lobe, dia-
phragmatic lung lobe, bronchial lymph node, retropharyngeal
lymph node, spleen and testes.
Sample analysis
TaqMan PCR assay for the detection of the NiV N gene,
immunohistochemical evaluation using a rabbit poly-
clonal antibody raised against the NiV N protein [36],
histology, serum neutralization titres against NiV and
virus isolation were carried out according to [22].
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